Sage Advisors’s Eli Lilly LLY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$20.8M Sell
19,397
-33
-0.2% -$31.6K 13.82% 2
2025
Q3
$14.8M Buy
19,430
+456
+2% +$339K 10.62% 4
2025
Q2
$14.8M Buy
18,974
+270
+1% +$210K 10.56% 3
2025
Q1
$15.4M Buy
18,704
+456
+2% +$379K 10.87% 4
2024
Q4
$14.1M Sell
18,248
-429
-2% -$355K 10.52% 4
2024
Q3
$16.5M Buy
18,677
+25
+0.1% +$22.5K 13.03% 4
2024
Q2
$16.9M Buy
18,652
+184
+1% +$147K 13.73% 3
2024
Q1
$14.4M Buy
18,468
+3,046
+20% +$2.17M 12.78% 3
2023
Q4
$8.99M Buy
+15,422
New +$9M 8.93% 5

Other funds holding LLY

Sage Advisors's LLY Position: Q4 2025 in Review

Sage Advisors reduced its Eli Lilly (LLY) stake by 0.17% in Q4 2025, selling an estimated $31.6K and leaving 19,397 shares worth $20.8M. The position accounts for 13.82% of the portfolio, ranked #2.

Sage Advisors first reported a position in LLY in Q4 2023 and has held it in 9 quarters since. 4,428 funds tracked by Wall St. Rank hold LLY as of Q4 2025.

  • Sage Advisors held 19,397 shares of Eli Lilly worth $20.8M as of Q4 2025.
  • Sage Advisors sold 33 Eli Lilly shares in Q4 2025, an estimated $31.6K.
  • Eli Lilly made up 13.82% of Sage Advisors's portfolio in Q4 2025, its #2 holding.
  • Sage Advisors first reported a position in Eli Lilly in Q4 2023 and has held it in 9 quarters since.
  • 4,428 funds tracked by Wall St. Rank held Eli Lilly as of Q4 2025.

Based on Sage Advisors's 13F filing for Q4 2025, filed 13 Jan 2026.